Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis

Cochrane Database of Systematic Reviews

Volumn , Issue 2, 2008, Pages

  Clerico, Marinella ^a   Faggiano, F ^b   Palace, J ^b   Rice, G ^b   Tintore M ^b   Durelli, L ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; IMMUNOMODULATING AGENT; INTERFERON BETA SERINE; PLACEBO;

CHILL; CLINICAL TRIAL; CLINICALLY DEFINITE MULTIPLE SCLEROSIS; CLINICALLY ISOLATED SYNDROME; DEMYELINATION; DEPRESSION; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; FEVER; FLU LIKE SYNDROME; FOLLOW UP; HUMAN; IMMUNOMODULATION; INJECTION SITE REACTION; META ANALYSIS; MULTIPLE SCLEROSIS; MYALGIA; RELAPSE; REVIEW; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 44949141642     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD005278.pub3     Document Type: Review

References (33)

1. BENEFIT 2006 {published and unpublished data} *Kappos L, Polman CH, Freedman MS, Edan G, Hartung HP, Miller DH, et al.Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006;67:1242-9.
2. CHAMPS 2000 {published data only} Beck RW, Chandler DL, Cole SR, Simon JH, Jacobs LD, Kinkel RP, et al.Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analyses. Annals of Neurology 2002;51(4):481-90.
3. CHAMPS STUDY GROUP. Interferon B-1a for Optic Neuritis Patients at High Risk for Multiple Sclerosis. American Journal of Ophtalmology 2001;132(4):463-71.
4. *Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, et al.Intramuscolar interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. New England Journal of Medicine 2000;343(13):898-904.
5. ETOMS, 2001 {published data only} *Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernandez O, et al.Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001;357(9268):1576-82.
6. Barkhof 2003 *Barkhof F, Rocca M, Francis G, Van Waesberghe JH, Uitdehaag BM, Hommes OR, et al. Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta 1a. Annals of Neurology 2003;53(3):718-24.
7. Comi 1995 *Comi G, Barkhof F, Durelli L, Edan G, Fernandez O, Filippi M, et al.Early treatment of multiple sclerosis with Rebif (recombinant human interferon beta): design of the study. Multiple Sclerosis 1995;1 Suppl 1:S24-S27.
8. Filippi 2004 *Filippi M, Rovaris M, Inglese M, Barkhof F, De Stefano N, Smith S, et al.Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double blind, placebo-controlled trial. Lancer 2004;364(9444): 1489-96.
9. Foroozan 2002 *Foroozan R, Buono LM, Savino PJ, Sergott RC. Acute demyelinating optic neuritis. Current Opinion in Ophthalmology 2002;16(6):375-80.
10. Galetta 2001 *Galetta SL. The controlled high risk Avonex multiple sclerosis trial (CHAMPS Study). Journal of Neuroophtalmology 2001;21(4):292-5.
11. Labetouelle 2001 *Labetouelle M. [ About the article: " Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis" by Jacobs LD et al.]. Journal Francais of Ophtalmology 2001;24(2):222.
12. O' Connor 2003 *O' Connor P. The effects of intramuscular interferon beta-1a in patients at high risk for development of multiple sclerosis: a post hoc analysis of data from CHAMPS. Clinical Therapy 2003;25(11):2865-74.
13. Siddiqui 2005 *Siddiqui MA, Wellington K. Intramuscular interferon-beta-1a: in patients at risk of developing clinically definite multiple sclerosis. CNS Drugs 2005;19(1):55-61.
14. Wermesch 2001 *Wermersch P. Are there arguments for initiating an etiological treatment at the onset of the first demyelinating episode?. Press Medicine 2004;33(3):180-6.
15. Altman 2001 Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D. The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration. Annals of Internal Medicine 2001;134:663-94.
16. Comi 2001A Comi G, Filippi M, Wolinsky JS. European/Canadian Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Effects of Glatiramer Acetate on Magnetic Resonance Imaging-Measured Disease Activity and Burden in Patients with Relapsing Multiple Sclerosis. Annals of Neurology 2001;49:290-7.
17. Deeks 2001 Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining hererogeneity and combining results from several studies in meta-analysis. In: EggerM, SmithGD, AltmanDG editor(s). Systematic reviews in Health Care. British Medical Journal, 2001:285-312.
18. Durelli 2002 Durelli L, Verdun E, Clerico M, Versino E. Immunomodulatory agents in multiple sclerosis: clinical trials and therapy. San Diego: Gilman S, 2002.
19. Ferguson 1997 Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain 1997;120:393-9.
20. Frohman 2003 Frohman EM, Goodin DS, Calabresi PA, Corboy JR, Coyle PK, Filippi M, et al.The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2003;61(5):602-11.
21. Fu 1998 Fu L, Matthews PM, De Stefano N, Worsley KJ, Narayanan S, Francis GS, et al.Imaging axonal damage of normal appearing whithe matter in multiple sclerosis. Brain 1998;121:103-13.
22. Higgins 2006 Higgins JPT, Gren S, editors. Cochrane handbook for Systematic Reviews of interventions 4.2.6 [ updated September 2006]. The Cochrane Library. John Wiley & sons, Ltd, 2006.
23. Jacobs 1996 Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et al.Intramuscolar interferon beta 1-a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Annals of Neurology 1996;39:285-94.
24. Johnson 1995 Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, et al.Copolymer 1 reduces rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995;45:1268-76.
25. La Mantia 2000 LaMantia L, Milanese C, D'Amico R. Meta-analysis of clinical trials with copolymer 1 in multiple sclerosis. European Neurology 2000;43(4):189-93.
26. Martinelli 2003 Martinelli Boneschi F, Rovaris M, Johnson KP, Miller A, Wolinsky JS, Ladkani D, et al.Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double blind, randomized, placebo-controlled clinical trials. Multiple Sclerosis 2003;9:349-55.
27. Mc Donald 2001 McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al.Recommended Diagnostic Criteria for Mutiple Sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Annals of Neurology 2001;50:121-7.
28. Munari 2003 Munari L, Lovati R, Boiko A. Therapy with glatiramer acetate for multiple sclerosis. Cochrane Database of Systematic Reviews 2003, Issue 4.Art. No.: CD004678. DOI:10.1002/14651858.CD004678.
29. Poser 1983 Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al.New diagnostic Criteria for Multiple Sclerosis: Guidelines for Research Protocols. Annals of Neurology 1983;13(3):227-31.
30. PRISMS 1998 The PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon beta -1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-504.
31. Rice 2001 Rice G PA, Incorvaia B, Munari L, Ebers G, Polman C, D'Amico R, et al.Interferon in relapsing-remitting multiple sclerosis. Cochrane Database of Systematic Reviews 2001, Issue 4.Art. No.: CD002002. DOI:10.1002/14651858.CD002002.
32. The IFNB 1993 The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of amulticenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-61.
33. Trapp 1998 Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L. Axonal transection in the lesions of multiple sclerosis. New England Journal of Medicine 1998;343:898-904.